Autoimmune diseases companies

Companies whose enriched business profile is tagged “Autoimmune diseases”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + Finnhub, shown with its as-of date.

• AbbVie (ABBV) Health Care — Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases. ask →
• DIANTHUS THERAPEUTICS INC (DNTH) Health Care — Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and inflammatory diseases. ask →
• CRISPR THERAPEUTICS AG (CRSP) Health Care — CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs. ask →
• ARCUS BIOSCIENCES INC (RCUS) Health Care — A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials. ask →
• CELLDEX THERAPEUTICS INC (CLDX) Health Care — A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin diseases, and systemic inflammatory conditions. ask →
• JADE BIOSCIENCES INC (JBIO) Health Care — Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA nephropathy and rheumatoid arthritis. ask →
• FORTE BIOSCIENCES INC (FBRX) Health Care — A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data and trials underway in vitiligo and alopecia areata. ask →
• AVALO THERAPEUTICS INC (AVTX) Health Care — Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026. ask →
• JANUX THERAPEUTICS INC (JANX) Health Care — Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of cancer and autoimmune treatments. ask →
• KYVERNA THERAPEUTICS INC (KYTX) Health Care — Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful clinical trial outcomes. ask →
• ELEDON PHARMACEUTICALS INC (ELDN) Health Care — Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation. ask →
• Immunic, Inc. (IMUX) Health Care — Immunic is a late-stage biotech developing oral small-molecule therapies for multiple sclerosis and gastrointestinal diseases with Phase 3 data expected in 2026. ask →
• Cue Biopharma, Inc. (CUE) Health Care — Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate anti-tumor immunity in cancer. ask →

Not quite it? Describe exactly what you want →

Data: SEC EDGAR (filings) + Finnhub (fundamentals, delayed daily-close). Figures shown with their as-of date.

Last updated 2026-07-22.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.